Oral mycosis fungoides with CD30+ large cell transformation successfully treated with brentuximab vedotin

Goggins, Clare A; Gocke, M. Timothy; Jang, Sekwon; DeSimone, Jennifer

doi:10.1016/j.jdcr.2018.11.013

Cited by 5 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the first reports of successful use of BV in MF-LCT was provided by Goggins et al [14] in 2019. They discussed the case of a patient with oral MF-LCT CD30+ from the IIB stage who presented an excellent response to the initial dose of BV and ~60% improvement of the Case Reports in Dermatology lesions (according to the physician's global assessment) after the second dose.…”

Section: Discussionmentioning

confidence: 99%

Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT

Giza¹,

Miklusiak²,

Hałubiec³

et al. 2023

Case Rep Dermatol

View full text Add to dashboard Cite

The large cell transformation of mycosis fungoides (MF-LCT) is a phenomenon observed in the advanced stages of mycosis fungoides (MF), which is the most common primary cutaneous lymphoma. The diagnostic criteria of MF-LCT are a minimum of 25% of large cells or a formation of microscopic nodules of them in the histological examination of skin samples. The clinical outcomes for MF-LCT are poor, as less than 20% of patients survive 5 years after diagnosis, but the expression of the CD30 antigen is generally considered to be associated with a better prognosis. We present a case of a patient with the diagnosis of MF with LCT, with an ulcerated tumor lesion approximately 30 × 20 cm in size on the right lateral abdominal wall. Brentuximab vedotin (BV) treatment was started due to the presence of the CD30 antigen, with a quick and impressive regression of the cutaneous lesion and tumor mass and good treatment tolerance. After follow-up of 20 months, patient remains in complete remission. A schedule of treatment for MF-LCT is directed mainly by the clinical stage of the disease and the comorbidities; the more severe clinical course of the disease requires systemic treatment. If at least 5% of the cells found in the skin lesions biopsy sample express the CD30 antigen, a beneficial effect of BV treatment could be expected. It may seem that the use of BV is one of the optimal therapeutic options in patients with advanced MF-LCT showing expression of CD30.

show abstract

Section: Discussionmentioning

confidence: 99%

Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT

Giza¹,

Miklusiak²,

Hałubiec³

et al. 2023

Case Rep Dermatol

View full text Add to dashboard Cite

show abstract

“… 3 , 4 , 5 An uncommon occurrence, LCT is estimated to occur in 6%-32% of MF cases, with a prognosis of <20% survival in 5 years. 1 , 4 …”

Section: Discussionmentioning

confidence: 99%

“…[3][4][5] An uncommon occurrence, LCT is estimated to occur in 6%-32% of MF cases, with a prognosis of \20% survival in 5 years. 1,4 The combination of LCT and oral involvement by MF is exceedingly rare, with only six cases reported to date (Table I), when restricted to those with detailed characterization. 1 While one article alludes to three cases of oral MF, only one case is highlighted in detail as qualifying as LCT.…”

Section: Discussionmentioning

confidence: 99%

“…1,4 The combination of LCT and oral involvement by MF is exceedingly rare, with only six cases reported to date (Table I), when restricted to those with detailed characterization. 1 While one article alludes to three cases of oral MF, only one case is highlighted in detail as qualifying as LCT. 8 Moreover, involvement of the upper lip by MF with LCT to our knowledge has not been previously documented.…”

Section: Discussionmentioning

confidence: 99%

“…Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, manifests a spectrum of cutaneous patches, plaques, and tumors, but only rarely involves the oral mucosa. 1 , 2 CD30 + large cell transformation (LCT) of MF generally heralds poor prognosis and occurs occasionally. 3 , 4 LCT of MF occurring in the oral mucosa is exceptional.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A mutilating, persistent lip ulcer as a presenting sign of oral mycosis fungoides with large cell transformation

et al. 2021

View full text Add to dashboard Cite

Oral Mycosis Fungoides: Report of 2 Cases and Review of the Literature

Alexander-Savino¹,

Boye-Doe²,

Bowers³

et al. 2023

Case Rep Dermatol

View full text Add to dashboard Cite

Oral and laryngeal cutaneous T-cell lymphoma (CTCL) is rare and usually associated with poor prognosis. Here, we discuss 2 cases of oral CTCL that developed in heavily pretreated patients and provide a review of the literature. The first case is of a 46-year-old African American male with rapidly progressive disease, presenting with a lesion on his hard palate 6 months after being diagnosed with a CD4+CD8+ CTCL. His cutaneous disease was widespread with tumors on >80% of his body surface area. Unfortunately, the patient died 2 ½ years after his CTCL diagnosis and 7 months after developing the oral CTCL lesion. The second case is of a 38-year-old African American male with stage IIb CD3+CD4+CD30+ mycosis fungoides (MF), who developed a tumor on the hard palate 6 months after diagnosis. He received palliative radiation to the oral lesion and multiple lines of systemic therapy for pulmonary, laryngeal, esophageal, and gastric involvement. Biopsy of the gastric lesions showed a CD30+ T-cell lymphoma with the same clonal peak as in his skin but with large cell transformation. Brentuximab vendoin was started, and the patient is now in complete remission, 30 months later. From the 76 cases of oral CTCL that have been reported in the English language, six were of transformed MF. The most common sites affected were the tongue and palate, and the most common presentation were erythematous or ulcerated tumors, plaques, or nodules associated with dysphagia and pain. Oral CTCL typically occurs years after the initial diagnosis of CTCL and portend a poor prognosis with an average survival of just over 1 year after development of oral lesions.

show abstract

Oral mycosis fungoides with CD30+ large cell transformation successfully treated with brentuximab vedotin

Cited by 5 publications

References 9 publications

Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT

Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT

A mutilating, persistent lip ulcer as a presenting sign of oral mycosis fungoides with large cell transformation

Oral Mycosis Fungoides: Report of 2 Cases and Review of the Literature

Contact Info

Product

Resources

About